Correction to: Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial

Kyoko Kikuno, Ryuta Asada, Takuma Ishihara, Ken-Ichirou Morishige, Kenro Chikazawa, Tatsuro Furui, Masanori Isobe
Advances in therapy · 2026 · vol. 43(2) , pp. 917 · doi:10.1007/s12325-025-03464-5 · PMID:41442031 · PMC12909403
other OA: gold CC-BY-NC-4.0
📄 Open PDF Full text JSON View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-08, 2026-08-04 ⓘ

This randomized, open-label trial evaluated the efficacy and safety of 48-week low-dose dienogest treatment for endometriosis-associated dysmenorrhea.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: pmc ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosisdysmenorrhea

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

SciLite annotations

chemicals 1
dienogest

Source provenance

europepmc
last seen: 2026-08-10T06:11:17.106188+00:00
pmc
last seen: 2026-05-13T20:22:03.195721+00:00
pubmed
last seen: 2026-08-10T06:07:20.832741+00:00
scilite
last seen: 2026-06-21T06:47:03.627287+00:00
unpaywall
last seen: 2026-05-11T08:34:28.763810+00:00
License: CC-BY-NC-4.0 · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine